Kiniksa Pharmaceuticals, Ltd.KNSANASDAQ
Loading
EBITDA Margin Over TimeExpanding
Percentile Rank100
3Y CAGR+31.6%
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

3Y CAGR
+31.6%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
2.3x
Strong expansion
Streak
1 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM12.61%+221.5%
2024-10.38%-22.7%
2023-8.46%-252.9%
20225.53%+101.4%
2021-400.27%-
20200.00%-
20190.00%-